Uniphar PLC - Half-Year Trading Update and Notice of Results

Uniphar plc
Half-Year Trading Update and Notice of Results
The business achieved ca. 11% adjusted EPS growth in the first half of 2026, in line with the Group's expectations, driven by a strong trading performance with ca. 7% organic gross profit growth.
Divisional performance:
· Uniphar Pharma delivered high single-digit organic gross profit growth during the period and is on track to deliver double-digit organic gross profit growth for the full year.
· Uniphar Medtech achieved high single-digit organic gross profit growth during the half and remains on track to deliver high single-digit organic gross profit growth for the full year.
· Uniphar Supply Chain & Retail delivered mid-single-digit organic gross profit growth during the half and is expected to deliver mid-single-digit organic gross profit growth for the full year.
The Group continues to maintain a strong liquidity position, with Net Bank Debt/EBITDA of 2.4x at the end of
Outlook and strategic update
Uniphar enters the second half of the year with strong trading momentum across the Group, and underlying trading expectations for the year remain unchanged.
The new high-tech distribution facility in
The revised timeline will defer associated depreciation and amortisation charges, resulting in a benefit to FY 2026 adjusted EPS expectations.
M&A continues to play an important role in Uniphar's growth strategy, and the Group maintains a disciplined approach to capital allocation, while managing an active pipeline of acquisition opportunities to further enhance the Group's growth potential.
"Uniphar has delivered a strong first half, with continued organic gross profit growth across the Group. Trading continues to be robust and the business is developing in line with our expectations. We expect to sustain this progress into the second half and remain on track to meet our growth objectives for each of our three divisions for the full year. We also remain confident in our ability to reach our
Notice of Results
The Group expects to publish its interim results for the six months ended
A conference call for analysts and investors will be held at
The Company's interim results press release and presentation will also be available on the website at
--- ENDS ---
Contact details
|
Uniphar Group
|
Tel: +353 (0) 1 428 7777 |
|
|
|
|
|
|
|
Davy (Joint Corporate Broker, Nominated Advisor and Euronext Growth Listing Sponsor)
|
Tel: +353 (0) 1 679 6363 |
|
|
|
|
|
|
|
RBC Capital Markets (Joint Corporate Broker)
|
Tel: +44 (0) 20 7653 4000 |
|
|
|
|
|
|
|
Stifel Nicolaus Europe Limited (Joint Corporate Broker)
|
Tel: +44 (0) 20 7710 7600 |
|
|
|
|
|
|
|
Q4 PR
|
Tel: +353 (0) 1 475 1444 |
|
|
|
About Uniphar plc
Headquartered in
The Company's vision is to improve patient access to pharmaco-medical products and treatments by enhancing connectivity between manufacturers and healthcare stakeholders. Uniphar represents a strong combination of scale, growth, and profitability.
Uniphar Supply Chain & Retail
Uniphar Supply Chain & Retail is the leading pharmaceutical wholesaler in
Uniphar Medtech
Uniphar Medtech is a leading Pan-European medical device distributor and solutions partner. The Group's strategy for Uniphar Medtech is to grow our service offering across
Uniphar Pharma
Uniphar Pharma operates a global business with high value services across the lifecycle of a pharmaceutical product. We enable pharma and biotech companies to bring innovative medicines to global markets and provide healthcare professionals with access to medicines they can't source through traditional channels. Our strategy is to build a leading platform to provide the specialist support and expertise needed to improve access to these medicines.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE